Data Coordinating CenterDouglas Curran-Everett*, Ruthie Knowles, Maura Robinson, and Lori Silveira
doi: 10.1210/jc.2019-00296 43
Do different PTM types (e.g., lactylation vs acetylation) exhibit competition or synergy under the same metabolite context
If you are interested in PQQ, consider how it fits into your broader goals
Survodutide, as a dual GLP-1/glucagon receptor agonist, further supports the plausibility of glucagon receptor activation as a useful therapeutic component when paired with GLP-1 signaling
People who are otherwise healthy may be less willing to accept these potentially serious adverse events. GLP-1 agonists were originally developed for managing Type 2 diabetes, but exploded in popularity over the past decade as an off-label weight-loss tool, reaching approximately 40 million prescriptions in the U.S